Form 4: Thermo Fisher EVP Sells Shares After Option Exercise

Thermo Fisher Scientific Executive Vice President Michael D. Shafer exercised stock options and subsequently sold 10,725 shares of common stock for $600 per share.

Summary

• Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific Inc. (TMO), reported transactions on November 25, 2025.
• Shafer exercised options to acquire 8,475 shares of common stock at an exercise price of $253.99 per share.
• Concurrently, Shafer exercised options to acquire an additional 2,250 shares of common stock at an exercise price of $294.02 per share.
• Immediately following the option exercises, Shafer disposed of 8,475 shares of common stock at a price of $600 per share.
• Additionally, Shafer disposed of 2,250 shares of common stock at a price of $600 per share.
• All reported dispositions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2024.
• Following these transactions, Shafer's direct beneficial ownership of common stock stands at 18,730.8026 shares.
• The options for 8,475 shares vested in four equal installments on February 26, 2020, 2021, 2022, and 2023, with an expiration date of February 26, 2026.
• The options for 2,250 shares vested in four equal installments on September 5, 2020, 2021, 2022, and 2023, with an expiration date of September 5, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the exercise of vested stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. While the insider profited, the transaction itself is expected and does not provide strong positive or negative signals regarding the company's future performance.

Positives

• The Executive Vice President realized a significant profit by exercising stock options at lower prices ($253.99 and $294.02) and selling the shares at a higher market price ($600).

Negatives

• An insider selling shares, even under a pre-arranged plan, could be interpreted by some investors as a signal that the executive does not anticipate substantial further upside in the near term, though it is often for personal financial planning.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view this as a routine, pre-planned transaction for personal financial management, which typically has minimal impact on sentiment.
• Some investors might interpret insider selling, even under a 10b5-1 plan, as a neutral to slightly negative signal, but the pre-planned nature mitigates significant concern.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of vested stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. This type of transaction is typically for personal financial planning and does not inherently signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter the investment thesis.

Keywords

Thermo Fisher Scientific, TMO, Insider Trading, Form 4, Stock Options, Executive Vice President, Share Sale, Rule 10b5-1